Urinary transforming growth factor-β1 in relation to serum α-fetoprotein in hepatocellular carcinoma

Scandinavian Journal of Gastroenterology

Volumn 32, Issue 3, 1997, Pages 254-260

  Tsai, J F ^a   Jeng, J E ^a   Chuang, L Y ^a   Chang, W Y ^a   Hsieh, M Y ^a   Lin, Z Y ^a   Tsai, J H ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

hepatocellular carcinoma; receiver operating characteristic curve; transforming growth factor 1; urine; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RADIOIMMUNOASSAY;

EID: 0031057165     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529709000203     Document Type: Article

References (30)

1. Roberts AB, Sporn MB. The transforming growth factor betas. In: Sporn MB, Roberts AB. editors. Peptide growth factors and their receptors. I. Heidelberg, Germany: Springer-Verlas, 1990: 414-72.
2. Roberts AB, Thompson NL, Heine U, Flanders C, Spron MB. Transforming growth factor-beta: possible roles in carcinogenesis. Br J Cancer 1988;57:594-600.
3. Bedossa P, Peltier E, Terris B, Franco D, Poynard T. Transforming growth factor-beta 1 (TGF-β1) and TGF-β1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 1995;21:760-6.
4. Carr BI, Hung TH, Itakura K, Noel M, Marceau N. TGF-β gene transcription in normal and neoplastic liver growth. J Cell Biochem 1989;39:477-87.
5. Shirai Y, Kawata S, Ito N, Tamura S, Takaishi K, Kiso S, et al. Elevated levels of plasma transforming growth factor-β in patients with hepatocellular carcinoma. Jpn J Cancer Res 1992; 83:676-9.
6. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, et al. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma. Cancer 1994;73:2275-9.
7. Ito N, Kawata S, Tamura S, Takaishi K, Yabuuchi I, Matsuda Y, et al. Expression of transforming growth factor-beta 1 mRNA in human hepatocellular carcinoma. Jpn J Cancer Res 1990;81: 1202-5.
8. Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, Kiso S, et al. Elevated levels of transforming growth factor-beta and its polypeptide in human hepatocellular carcinoma. Cancer Res 1991;15:4080-3.
9. Okuda K, Kondo Y. Primary carcinoma of the liver. In: Haubrich WS, Schaffner F, Berk JE, editors. Bokus gastroenterology. 5th ed. Philadelphia: WB Saunders, 1995:2444-87.
10. Yachin S. The immunosuppressive properties of alpha-fetoprotein: a brief overview. Ann NY Acad Sci 1983;417:105-7.
11. Palladino MA, Morris RE, Starnes HF, Levinson AD. The transforming growth factor-betas: a new family of immunoregulatory molecules. Ann NY Acad Sci 1991;593:231-42.
12. Nakao K, Nakata K, Mitsuoka S, Ohtsuru A, Ido A, Hatano M, et al. Transforming growth factor β1 differentially regulates α-fetoprotein and albumin in HuH-7 human hepatoma cells. Biochem Biophys Res Commun 1991;174:1294-9.
13. Sherwin SA, Twardzik DR, Bohn WH, Cockley KD, Todaro GJ. High-molecular-weight transforming growth factor activity in the urine of patients with disseminated cancer. Cancer Res 1983;43:403-7.
14. Sox HC, Blatt MA, Higgins MC, Marion K Medical decision making, London: Butterworth & Co. Ltd, 1989:37-146.
15. Colombo M. Should patients with chronic viral hepatitis be creened for hepatocellular carcinoma? Viral Hepatitis Rev 1995;1:67-75.
16. Jeng JE, Tsai JF. Hepatitis C virus antibody in hepatocellular carcinoma in Taiwan. J Med Virol 1991;34:74-7.
17. Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY. Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. Br J Cancer 1996;73:1498-502.
18. Tsai JF, Jeng JE, Chang WY, Ho MS, Lin ZY, Tsai JH. Clinical evaluation of serum α-fetoprotein and circulating immune complexes as tumor markers of hepatocellular carcinoma. Br J Cancer 1995;72:442-6.
19. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Hepatitis B and C virus infection as risk factors for Chinese hepatocellular carcinoma: a case-control study. Int J Cancer 1994;56:619-21.
20. Tsai JF, Chang WY, Jeng JH, Ho MS, Lin ZY, Tsai JH. Effects of hepatitis C and B viruses infection on the development of hepatocellular carcinoma. J Med Virol 1994;44:92-5.
21. Tsai JF, Chang WY, Jeng JH, Ho MS, Lin ZY, Tsai JH. Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver 1994;14:98-102.
22. Tsai JF, Jeng JE, Ho MS, Lin ZY, Tsai JH. Frequency of raised alpha-fetoprotein level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C. Br J Cancer 1994; 69:1157-9.
23. Tsai JF, Margolis HS, Jeng JH, Ho MS, Ko YC, Lin ZY, et al. Association between hepatitis B and C virus infection and Chinese hepatocellular carcinoma: a case-control study. In: Nishioka K, Suzuki H, Mishiro S, Oda T, editors. Viral hepatitis and liver disease. Tokyo: Springer-Verlag, 1994:697-700.
24. Tsai JF, Chang WY, Jeng JE, Ho MS, Wang LY, Hsieh MY, et al. Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol 1993;41:296-300.
25. Tsai JF, Jeng JE, Chang WY, Lin ZY, Tsai JH. Hepatitis C virus infection among patients with chronic liver disease in an area hyperendemic for hepatitis B. Scand J Gastroenterol 1944;24: 550-2.
26. Tsai JF, Tsai JH, Chang WY. Relationship of serum α-feto protein to circulating immune complexes and complements in patients with hepatitis B surface antigen-positive hepatocellular carcinoma. Gastroenterol Jpn 1990;25:388-93.
27. Tsai JF, Tsai JH, Chang WY, Ton TC. Elevation of circulating immune complexes and its relationship to α-fetoprotein levels in patients with hepatitis B surface antigen-positive hepatocellular carcinoma. Cancer Invest 1991;4:137-43.
28. Chuang LY, Hon WC, Yang ML, Chang CC, Tsai JF. Urinary epidermal growth factor receptor-binding growth factors in the tumors of the digestive tract. Clin Biochem 1994;27:485-9.
29. Maussier ML, Valenza V, Schinco G, Galli G. AFP, CEA, CA19-9 and TPA in hepatocellular carcinoma. Int J Biol Markers 1990;5:121-6.
30. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988;240:1285-93.